COMP <GO>
MGX vs EVAX // RSI-14 & 200D SMA MOMENTUM
Metagenomi Therapeutics Inc. (NASDAQ) VS. Evaxion A/S (NASDAQ) • 15-METRIC TALLY: MGX 1
— EVAX 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: EVAX
LAST: $0.83 (+1.03%) • MKT CAP: $31.4M
rsi-technicals
30.9
LAST: $3.08 (-0.96%) • MKT CAP: $27.8M
rsi-technicals
43.0
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MGX VS. EVAX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MGX | EVAX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -51.80% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 30.9 | 43.0 | -12.03 | EVAX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $31.4M | $27.8M | $3.6M | MGX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MGX REV | EVAX REV | MGX GROSS % | EVAX GROSS % | MGX FCF | EVAX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $25.2M | — | — | — | -$89.5M | — |
| FY 2024 | $52.3M | — | — | — | -$112.2M | — |
| FY 2023 | $44.8M | — | — | — | -$91.4M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MGX // BETA —
EVAX // BETA —